GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,448.50p
   
  • Change Today:
    -14.50p
  • 52 Week High: 1,812.50
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,109.73m
  • Volume: 7,904,168
  • Market Cap: £59,530m
  • RiskGrade: 129

Financial Analysis

Select chart: EPS | Dividend | Revenue

Latest Interim/Quarterly

Period Ending Period Revenue (£m) Pre-tax (£m) EPS Dividend
31-Mar-25 Q1 7,516.00 2,108.00 44.90p n/a

Key Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 32,509.71 9,209.14 165.95p 8.7 2.1 +4% 64.64p 0.0%
31-Dec-26 34,261.41 10,116.33 185.08p 7.8 0.7 +12% 69.06p 0.0%
31-Dec-27 35,615.40 10,706.20 195.96p 7.4 1.3 +6% 73.29p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Price / Earnings Data

5 Yr High 5 Yr Low 5 Yr Avg Curr / Avg
Latest 14.47 8.45 12.95 0.70

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

GSK Market Data

Currency UK Pounds
Share Price 1,448.50p
Change Today -14.50p
% Change -0.99 %
52 Week High 1,812.50
52 Week Low 1,264.00
Volume 7,904,168
Shares Issued 4,109.73m
Market Cap £59,530m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
40.4% below the market average40.4% below the market average40.4% below the market average40.4% below the market average40.4% below the market average
Sector averageSector averageSector averageSector averageSector average
Price Trend
3.93% above the market average3.93% above the market average3.93% above the market average3.93% above the market average3.93% above the market average
45.83% above the sector average45.83% above the sector average45.83% above the sector average45.83% above the sector average45.83% above the sector average
Income
70.69% above the market average70.69% above the market average70.69% above the market average70.69% above the market average70.69% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
42.25% below the market average42.25% below the market average42.25% below the market average42.25% below the market average42.25% below the market average
37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 02-May-2025

Time Volume / Share Price
16:26 0 @ 1,449.00p
16:26 2 @ 1,449.00p
16:26 2 @ 1,449.00p
16:26 0 @ 1,449.00p
16:26 6 @ 1,449.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page